Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. - Wikidata - wikimedia - TriplyDB

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

http://www.wikidata.org/entity/Q44315387

about

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors Advances in the treatment of relapsed or refractory Hodgkin's lymphoma Hodgkin lymphoma, version 2.2015.Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.ABVE-PC and modified BEACOPP regimen in Indian children with Hodgkin lymphoma: Feasibility and efficacy Role of chemotherapy in Hodgkin's lymphoma.Clinical features and treatment outcomes of Hodgkin's lymphoma in Hong Kong Chinese.Hodgkin lymphoma in a thymic cyst: report of a case with multiple secondary neoplasms Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma.Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma Hodgkin's lymphoma therapy: past, present, and future.Incidence patterns and outcomes for hodgkin lymphoma patients in the United States Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas.A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.The case for chemotherapy alone for limited-stage Hodgkin's lymphoma.Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas.A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.Involved site radiation therapy for the treatment of early-stage Hodgkin lymphoma in adolescents and young adults Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up

P2860

Q24234975-5F810C72-A936-4A3D-AA72-B82D7A5839DE Q24683022-3C3E496C-34B1-41FF-BCB7-21B6B2D00145 Q27694504-DF2E0AA2-CB7E-4812-98FA-BE66566D7BFC Q30769157-035FE3C3-EFE1-4A65-86AB-6C9339586E9F Q33404875-C6A77FCF-92CD-4916-8F0F-2BA5ABF9D47A Q33432165-31115B82-601D-471F-AC42-52B364E8F9A6 Q33761103-E5847114-F715-4DA4-8762-CC8116B6968A Q33935351-6F863B1A-7FD9-4A4E-ABC0-55B776BDFFDE Q33943212-A8C49758-4BD4-4D14-A8F2-C4542EB88CFA Q34095620-C105BC52-1AB3-43A6-B31A-B4F0BF6A0C17 Q34104990-2EC6CA41-9638-46A7-9407-99DD9F4851A0 Q34235785-93076858-B1D0-4A45-8BCF-2BD77029A2A4 Q34296914-DDBAC998-95E0-4B86-B5DE-FE635A985A96 Q34442533-436D627B-1AB0-4F67-B97B-BB75C9966F90 Q34501005-27DC83E2-47E1-4CA8-8DB3-48941D094D7A Q34553446-09EBD3C2-8A49-4BFF-B0D2-FBD9B9FB25AB Q34583406-D4E58C62-03D8-4BD8-B77F-4A840E0E0CF5 Q34645722-CE306F7C-F968-41C6-9CD7-18674640B6AD Q34662648-9EBCEF98-2BA4-4066-BFE2-3108671E587F Q34738140-B5035D30-4017-4693-8164-74E507F7D17A Q34778364-856AEC71-F6B6-4ECB-A3AD-2661A297C0EE Q35038832-B1A9A7F4-D970-4B46-B55C-B8F4746A4626 Q35038852-9C31D2AA-B337-4FD1-9A7A-AB911E72A43A Q35631349-E6B96A32-6796-4545-AA9F-5B267E339DE2 Q35669134-CAA8C0B1-3BCC-49D5-AF30-9D770547C2C6 Q35705317-0336A957-766A-4028-B01F-1922B431FAD1 Q35717972-FB18200E-A7C4-4CEA-83C2-1C0FC8FC8092 Q35754532-87625E4D-ABA7-418E-BAD6-58482DCA8A48 Q35986604-9212063E-152A-440C-8B30-E33ECAAEBFDE Q36135751-18F62419-A619-41EC-81C8-2B1FDC4C5097 Q36182790-F297C685-BB2A-4511-A4E8-C27F99826161 Q36283067-3DA7E4ED-5AAD-4FEE-A5E3-770D4EA90B23 Q36337623-ACAAFDB5-3BF4-40DB-9F74-8F47E3C6FA41 Q36450854-0C3F47BC-1257-4501-A0DB-246938C88BC7 Q36508102-0BDF77E0-CF8E-472C-895E-840D5E13A867 Q36862523-9C00842C-CFD0-4CD5-AC70-8CB3222F4E3B Q37091269-9F950B9B-52E2-4E54-9301-F9736C0DF2E4 Q37126978-67565CC5-6445-4B92-9ECC-04D8E2A3B497 Q37138259-99E3C444-4331-4F58-B46E-0B895A5B7053 Q37146056-A978A320-696D-4AC9-8C53-0026BFA03353

P2860

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

http://www.wikidata.org/entity/Q44315387

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Randomized comparison of ABVD ...... report of an intergroup trial.

@en

Randomized comparison of ABVD ...... report of an intergroup trial.

@nl

type

label

Randomized comparison of ABVD ...... report of an intergroup trial.

@en

Randomized comparison of ABVD ...... report of an intergroup trial.

@nl

prefLabel

Randomized comparison of ABVD ...... report of an intergroup trial.

@en

Randomized comparison of ABVD ...... report of an intergroup trial.

@nl

P1433

Q44315387-7F55D383-8992-4B3C-9715-DBE89BB9F715

P1476

Q44315387-D48EFEBD-8749-41A5-AA11-0972C1AEBEF1

P2093

Q44315387-02946916-5A3B-4CB6-86E8-02A575A64B27

Q44315387-1B511CD0-17B6-4ADD-A370-BBE55F98D9D9

Q44315387-378E1A2C-133E-43C0-B4E9-57CA12E495B5

Q44315387-4AAECE45-B68B-4A53-8582-A9E8EB5E063B

Q44315387-84607286-9431-474A-957E-E659E50C46EB

Q44315387-C65FA289-9243-46B7-8930-D55C542D7E32

Q44315387-DFEBA52D-E46F-4480-A045-53F9E094F9E6

P304

Q44315387-E338331C-D7F9-4DA2-B52C-B24407D9EA28

P31

Q44315387-88FA0F3C-BFB2-404A-991E-679A6382B1E2

P356

Q44315387-52AB75F8-3025-414A-9206-357599DD2D09

P407

Q44315387-3AEDA7B0-1A0B-4372-AD17-81D2AC13F714

P433

Q44315387-14434A13-5A39-4616-BA5C-8BB687364694

P478

Q44315387-7E7F8FC8-697F-4CAE-A442-6DF81D40CF2A

P50

Q44315387-A10FFAF3-2AA2-4B56-A041-D50E69B5CFFA

P577

Q44315387-78A38DF8-B630-4E86-AC0B-A0B9B4936663

P698

Q44315387-B73B20D1-7EE5-4260-B029-1B55B1862BF4

P356

JCO.2003.12.086

P1433

Journal of Clinical Oncology

P1476

Randomized comparison of ABVD ...... report of an intergroup trial.

@en

P2093

Bruce A Peterson

http://www.w3.org/2001/XMLSchema#string

David B Duggan

http://www.w3.org/2001/XMLSchema#string

George P Canellos

http://www.w3.org/2001/XMLSchema#string

Gina R Petroni

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Johnson

http://www.w3.org/2001/XMLSchema#string

John H Glick

http://www.w3.org/2001/XMLSchema#string

Richard I Fisher

http://www.w3.org/2001/XMLSchema#string

P304

607-614

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.12.086

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Joseph M Connors

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12586796

http://www.w3.org/2001/XMLSchema#string